One prosthetic group evaluated is known as N-succinimidyl-3-guanidinomethyl-5[131I]iodobenzbate (SGMIB), and when it was used to radiolabel an anti-HER2 Nb, 5F7, improved tumor targeting was observed [75]. This evidence concerns the gene ERBB2 and neoplasm.